Clinical trial management and monitoring MCQs With Answer

Clinical trial management and monitoring MCQs With Answer

Clinical trial management and monitoring is a core subject for B. Pharm students, covering study design, protocol adherence, site management, case report form (CRF) handling, informed consent, safety reporting, and regulatory compliance. This concise introduction emphasizes practical concepts—Good Clinical Practice (GCP), ICH guidelines, standard operating procedures (SOPs), quality assurance, risk-based monitoring, data integrity (ALCOA+), source document verification, and investigator responsibilities—essential for successful trials. Understanding monitoring tools, visit schedules, deviation management, adverse event reporting, investigational product accountability, and documentation strengthens competency for industry or regulatory roles. Now let’s test your knowledge with 30 MCQs on this topic.

Q1. What is the primary role of a Clinical Research Associate (CRA) or monitor?

• Design the study protocol
• Oversee site selection only
• Ensure subject safety and data integrity through site monitoring
• Perform laboratory assays for the trial

Correct Answer: Ensure subject safety and data integrity through site monitoring

Q2. Which activity is a key objective of on‑site monitoring visits?

• Conducting all statistical analyses
• Source document verification (SDV) and review of informed consent
• Marketing the investigational product
• Authoring the Investigator’s Brochure

Correct Answer: Source document verification (SDV) and review of informed consent

Q3. Which of the following best describes a Case Report Form (CRF)?

• A regulatory approval document
• The source document for all clinical data
• A paper or electronic form for collecting trial data about each subject
• A financial invoice for trial costs

Correct Answer: A paper or electronic form for collecting trial data about each subject

Q4. What does ALCOA stand for in clinical data quality?

• Attributable, Legible, Contemporaneous, Original, Accurate
• Available, Legitimate, Correct, Original, Archived
• Authentic, Legible, Complete, Organized, Accurate
• Attributable, Linked, Consistent, Observable, Accurate

Correct Answer: Attributable, Legible, Contemporaneous, Original, Accurate

Q5. According to ICH‑GCP, who is primarily responsible for obtaining informed consent?

• The Sponsor’s medical monitor
• The Investigator or delegated qualified member of the study team
• The data manager
• The ethics committee (IRB/IEC)

Correct Answer: The Investigator or delegated qualified member of the study team

Q6. Which document contains preclinical and clinical information on the investigational product for investigators?

• Case Report Form (CRF)
• Investigator’s Brochure (IB)
• Trial Master File (TMF)
• Monitoring Plan

Correct Answer: Investigator’s Brochure (IB)

Q7. What is the main purpose of risk‑based monitoring (RBM)?

• To eliminate the need for monitoring altogether
• To prioritize monitoring activities based on critical data and processes
• To increase the number of on‑site visits uniformly across sites
• To outsource monitoring to contract laboratories

Correct Answer: To prioritize monitoring activities based on critical data and processes

Q8. Which of the following is an essential component of a Monitoring Plan?

• Frequency of monitoring visits and extent of SDV
• Marketing strategy for the investigational product
• Laboratory assay protocols unrelated to the trial
• Financial audit procedures for unrelated departments

Correct Answer: Frequency of monitoring visits and extent of SDV

Q9. What is a Serious Adverse Event (SAE) reporting requirement to the sponsor from the investigator?

• Report SAEs only at the end of the study
• Report SAEs promptly, typically within 24 hours of awareness
• Report SAEs only if the subject requests it
• No reporting is required for SAEs

Correct Answer: Report SAEs promptly, typically within 24 hours of awareness

Q10. Which element is NOT part of Good Clinical Practice (GCP) principles?

• Protection of trial subjects’ rights, safety, and well‑being
• Integrity and credibility of trial data
• Mandatory publication of participant names
• Qualification of investigators and study staff

Correct Answer: Mandatory publication of participant names

Q11. Which regulatory document provides guidance on essential documents to be maintained during a clinical trial?

• ICH E6 (GCP) guideline
• Pharmacopoeia monograph
• Good Manufacturing Practice (GMP) only
• ICH Q9 on Quality Risk Management only

Correct Answer: ICH E6 (GCP) guideline

Q12. What is source data verification (SDV)?

• Checking that the investigational product label is correct
• Comparing data entered in the CRF/eCRF with original source documents
• Verifying the sponsor’s bank statements
• Reviewing only the consent form signature page

Correct Answer: Comparing data entered in the CRF/eCRF with original source documents

Q13. Which practice improves data integrity in eCRFs aligned with regulatory expectations?

• Using uncontrolled spreadsheets only
• Implementing validated systems with audit trails and controlled access
• Allowing multiple users to share one login
• Disabling electronic signatures

Correct Answer: Implementing validated systems with audit trails and controlled access

Q14. Which of these best describes a protocol deviation?

• A deliberate investigator decision to enhance efficacy
• Any noncompliance with the protocol, GCP, or applicable regulations
• A planned amendment approved before implementation
• Routine documentation of study visits

Correct Answer: Any noncompliance with the protocol, GCP, or applicable regulations

Q15. What does IMP accountability refer to?

• Tracking investigational product dispensing, receipt, storage, and return/destruction
• Counting study staff hours
• Scheduling monitoring visits only
• Submitting manuscripts to journals

Correct Answer: Tracking investigational product dispensing, receipt, storage, and return/destruction

Q16. What is the purpose of randomization in clinical trials?

• To increase investigator bias
• To allocate subjects to treatment groups and reduce selection bias
• To allow patients to choose their treatment
• To ensure unequal group sizes

Correct Answer: To allocate subjects to treatment groups and reduce selection bias

Q17. Which statement about blinding is correct?

• Single‑blind means both subject and investigator are unaware of treatment
• Double‑blind means only the sponsor is blinded
• Single‑blind means the subject is unaware of the assigned treatment
• Blinding is never used in randomized controlled trials

Correct Answer: Single‑blind means the subject is unaware of the assigned treatment

Q18. Who is responsible for ensuring trial conduct complies with the approved protocol and GCP?

• The Investigator at the trial site
• The local pharmacy only
• The clinical laboratory only
• The study subjects

Correct Answer: The Investigator at the trial site

Q19. Which body must approve the clinical trial protocol and informed consent before study initiation?

• Data Safety Monitoring Board (DSMB) only
• Institutional Review Board / Independent Ethics Committee (IRB/IEC)
• The study monitor without external review
• The clinical supplies vendor

Correct Answer: Institutional Review Board / Independent Ethics Committee (IRB/IEC)

Q20. What is a Trial Master File (TMF)?

• The file containing all financial invoices unrelated to the trial
• The collection of essential documents that describe the conduct of a clinical trial
• A randomization schedule only
• An investigator’s private notes kept outside sponsor oversight

Correct Answer: The collection of essential documents that describe the conduct of a clinical trial

Q21. What are Standard Operating Procedures (SOPs) used for in clinical trials?

• To set consistent, documented processes for trial activities and ensure quality
• To recruit subjects directly without consent
• To replace the protocol entirely
• To manage only financial matters

Correct Answer: To set consistent, documented processes for trial activities and ensure quality

Q22. Which is a common outcome of data queries raised during monitoring?

• Data are deleted immediately
• Clarification from site and correction or annotation of CRF/eCRF entries
• Investigator is removed from the trial
• Study is automatically terminated

Correct Answer: Clarification from site and correction or annotation of CRF/eCRF entries

Q23. Which items should IMPLICITLY appear in an investigational drug accountability log?

• Subject ID, date dispensed, quantity dispensed/returned, and investigator signature
• Only the study title and sponsor name
• Laboratory reference ranges
• Marketing authorisation details for approved drugs

Correct Answer: Subject ID, date dispensed, quantity dispensed/returned, and investigator signature

Q24. According to ICH‑GCP, for how long should essential documents generally be retained after trial completion?

• At least 2 years after the last approval of a marketing application in an ICH region
• Only until database lock
• Until the first monitoring visit
• Indefinitely with no sponsor responsibility

Correct Answer: At least 2 years after the last approval of a marketing application in an ICH region

Q25. Which is a key advantage of using eCRFs over paper CRFs?

• Elimination of all regulatory requirements
• Real‑time data checks, audit trails, faster query resolution, and centralized data access
• Complete removal of need for monitoring
• Lower data security standards

Correct Answer: Real‑time data checks, audit trails, faster query resolution, and centralized data access

Q26. What is the regulatory reporting timeframe for a fatal or life‑threatening SUSAR to regulatory authorities in many regions?

• Within 90 days
• Within 7 calendar days for initial report, with follow‑up within 8 days
• Only at study end
• No reporting required for SUSARs

Correct Answer: Within 7 calendar days for initial report, with follow‑up within 8 days

Q27. Who typically performs initial causality assessment of an adverse event?

• The Investigator at the site evaluates causality; the sponsor may also assess
• The monitor alone without site input
• The subject’s family members
• The pharmacy technician only

Correct Answer: The Investigator at the site evaluates causality; the sponsor may also assess

Q28. What does CAPA stand for in clinical quality management?

• Corrective and Preventive Action
• Clinical Assessment of Patient Adherence
• Compliance and Protocol Approval
• Centralized Analysis of Patient Activity

Correct Answer: Corrective and Preventive Action

Q29. What is the primary subject of 21 CFR Part 11 (US FDA)?

• Pharmaceutical manufacturing GMP only
• Electronic records and electronic signatures
• Good Laboratory Practice only
• Labeling requirements for over‑the‑counter drugs

Correct Answer: Electronic records and electronic signatures

Q30. Which activity is part of a sponsor’s quality assurance (QA) responsibilities?

• Monitoring and auditing to ensure trial compliance and data quality
• Providing medical care to subjects unrelated to the trial
• Designing only the clinical laboratory equipment
• Recruiting subjects for unrelated trials

Correct Answer: Monitoring and auditing to ensure trial compliance and data quality

Download